Article citationsMore >>

Payandeh M, Sadeghi E, Sadeghi M, Eskandar AM. Different Presentation of Treatment in Carcinomatous Meningitis of Breast Cancer: Report of 3 Cases, American Journal of Cancer Prevention, 3 (1), 4-7, 2015.

has been cited by the following article:

Article

Clinicopathology Figures of Breast Cancer Women with Brain Metastasis and Invasive Ductal Carcinoma

1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Breast Diseases Department, Breast Cancer Research Centre, ACECR, Iran

3Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

4Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran


American Journal of Cancer Prevention. 2015, Vol. 3 No. 3, 68-71
DOI: 10.12691/ajcp-3-3-6
Copyright © 2015 Science and Education Publishing

Cite this paper:
Mehrnoush Aeinfar, Safa Najafi, Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi. Clinicopathology Figures of Breast Cancer Women with Brain Metastasis and Invasive Ductal Carcinoma. American Journal of Cancer Prevention. 2015; 3(3):68-71. doi: 10.12691/ajcp-3-3-6.

Correspondence to: Masoud  Sadeghi, Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: Sadeghi_mbrc@yahoo.com

Abstract

Background: Breast cancer (BC) metastasis to the central nervous system (CNS) or brain metastases include the clinically distinct situations of multiple brain metastasis (78%), solitary brain metastasis (14%), and leptomeningeal metastasis (8%). The aim of this study is to describe clinicopathologic features of patients with BC brain metastasis and to compare estrogen receptor (ER), progesterone receptor (PR), and Her2 expression in them. Materials and Methods: there were 16 patients with brain metastasis and we entered them to our study. Age, sex, kind of pathology, tumor markers, type of treatment, histological grade, size of tumor, laterality and other metastasizes were checked for the patients. ER and PR positivity was defined as ≥10% positive tumor cells with nuclear staining. HER2 positivity was defined as either HER2 gene amplification by fluorescent in situ hybridization or scored as 3+ by IHC. Results: The mean age at diagnosis for the patients was 42.2 years (±14.4) and range of 27 to 73 years that 100% were female. ER, PR, Her-2 and p53 positive for the patients were 43.7%, 56.3%, 43.7% and 37.5%, respectively. Three patients (18.7%) had grade I, nine patients (56.3%) had grade II and four patients (25%) had grade III. The mean OS was 24.7 months with survival rate of 50%. Lymph node metastasis for 13 patients (81.2%) was positive. Conclusions: The mean age for patients with brain metastatic BC at diagnosis is more between 45 to 52 years and also brain metastasis in BC occurs more in HER-2-overexpressing and TNBC. Size of tumor in BC patients >5 cm is a prognostic factor for brain metastasis.

Keywords